Terms: = Head and neck cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2
527 results:
1. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
2. Genetic alterations and allele frequency of BRAF V600E and tert mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study.
Huang J; Wang J; Xv J; Wang J; Wang G; Zhao Y
Clin Exp Med; 2024 Apr; 24(1):76. PubMed ID: 38607456
[TBL] [Abstract] [Full Text] [Related]
3. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
[TBL] [Abstract] [Full Text] [Related]
4. Clinical features combined with ultrasound characteristics to predict tert promoter mutations in papillary thyroid carcinoma: a single-center study over the past 5 years.
Hu Y; Xu S; Dong L; Pan Z; Zhang L; Zhan W
Front Endocrinol (Lausanne); 2024; 15():1322731. PubMed ID: 38562417
[TBL] [Abstract] [Full Text] [Related]
5. Papillary thyroid carcinoma tall cell subtype (PTC-TC) and high-grade differentiated thyroid carcinoma tall cell phenotype (HGDTC-TC) have different clinical behaviour: a retrospective study of 1456 patients.
Ghossein R; Katabi N; Dogan S; Shaha AR; Tuttle RM; Fagin JA; Ganly I; Xu B
Histopathology; 2024 Jun; 84(7):1130-1138. PubMed ID: 38528726
[TBL] [Abstract] [Full Text] [Related]
6. The Role of 5-Hydroxymethylcytosine as a Potential Epigenetic Biomarker in a Large Series of Thyroid Neoplasms.
Canberk S; Gonçalves J; Rios E; Povoa AA; Tastekin E; Sobrinho-Simões M; Uguz A; Aydin O; Ince U; Soares P; Máximo V
Endocr Pathol; 2024 Mar; 35(1):25-39. PubMed ID: 38285158
[TBL] [Abstract] [Full Text] [Related]
7. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
8. Clinical and molecular features of progressive papillary thyroid microcarcinoma.
Wang Z; Ji X; Zhang H; Sun W
Int J Surg; 2024 Apr; 110(4):2313-2322. PubMed ID: 38241301
[TBL] [Abstract] [Full Text] [Related]
9. Association of Ultrasonography Features of Follicular Thyroid Carcinoma With Tumor Invasiveness and Prognosis Based on WHO Classification and tert Promoter Mutation.
Kim MK; Park H; Oh YL; Shin JH; Kim TH; Hahn SY
Korean J Radiol; 2024 Jan; 25(1):103-112. PubMed ID: 38184773
[TBL] [Abstract] [Full Text] [Related]
10. Characterization of integrated hepatitis B virus DNA harboring pre-S mutations in hepatocellular carcinoma patients with ground glass hepatocytes.
Su YP; Lin SY; Su IJ; Kao YL; Shen SC; Earl JP; Ehrlich GD; Chen CY; Huang W; Su YH; Tsai HW
J Med Virol; 2024 Jan; 96(1):e29348. PubMed ID: 38180275
[TBL] [Abstract] [Full Text] [Related]
11. Genetic predisposition to differentiated thyroid cancer in the Polish population.
Borowczyk M; Sypniewski M; Szyda J; Braszka M; Ziemnicka K; Ruchała M; Oszywa M; Król ZJ; Dobosz P
Pol Arch Intern Med; 2024 Mar; 134(3):. PubMed ID: 38165228
[TBL] [Abstract] [Full Text] [Related]
12. Establishment and Characterization of Amitrole-Induced Mouse Thyroid Adenomatous Nodule-Derived Cell Lines.
Shirai YT; Hoshi N; Ward JM; Liu H; Cachau RE; Lee MP; Kimura S
Thyroid; 2024 Apr; 34(4):496-509. PubMed ID: 38149583
[No Abstract] [Full Text] [Related]
13. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract] [Full Text] [Related]
14. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
[TBL] [Abstract] [Full Text] [Related]
15. A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma.
Germani MM; Boccaccio C; Matrone A; Molinaro E; Alì G; Giordano M; Elisei R; Fontanini G; Cremolini C
Oncologist; 2024 Jan; 29(1):84-88. PubMed ID: 38037189
[TBL] [Abstract] [Full Text] [Related]
16. Genomic profiling of primary and metastatic thyroid cancers.
Máximo V; Melo M; Zhu Y; Gazzo A; Sobrinho Simões M; Da Cruz Paula A; Soares P
Endocr Relat Cancer; 2024 Feb; 31(2):. PubMed ID: 38015791
[TBL] [Abstract] [Full Text] [Related]
17. Gene mutations as predictors of central lymph mode metastasis in cN0 PTC: A meta-analysis.
Ji J; Shi X
Clin Genet; 2024 Feb; 105(2):130-139. PubMed ID: 37985961
[TBL] [Abstract] [Full Text] [Related]
18. Age-associated mortality is partially mediated by tert promoter mutation status in differentiated thyroid carcinoma.
Heo J; Lee S; Park J; Yang H; Park H; Ki CS; Oh YL; Kim HI; Kim SW; Chung JH; Kim K; Kim TH
PLoS One; 2023; 18(11):e0294145. PubMed ID: 37948420
[TBL] [Abstract] [Full Text] [Related]
19. Risk-stratified Distant Metastatic Thyroid cancer with Clinicopathological Factors and BRAF/tert Promoter Mutations.
Cheng X; Zhou Y; Xu S; Yu H; Wu J; Bao J; Zhang L
Exp Clin Endocrinol Diabetes; 2023 Nov; 131(11):577-582. PubMed ID: 37922948
[TBL] [Abstract] [Full Text] [Related]
20. Loss of CDH16 expression is a strong independent predictor for lymph node metastasis in Middle Eastern papillary thyroid cancer.
Siraj AK; Parvathareddy SK; Al-Rasheed M; Annaiyappanaidu P; Siraj N; Lennartz M; Al-Sobhi SS; Al-Dayel F; Sauter G; Al-Kuraya KS
Sci Rep; 2023 Oct; 13(1):18559. PubMed ID: 37899424
[TBL] [Abstract] [Full Text] [Related]
[Next]